耐甲氧西林金黄色葡萄球菌抗菌策略研究进展

doi:10.16150/j.1671-2870.2026.03.013

诊断学理论与实践 ›› 2026, Vol. 25 ›› Issue (03): 361-369.doi: 10.16150/j.1671-2870.2026.03.013

耐甲氧西林金黄色葡萄球菌抗菌策略研究进展

李梦娜¹^,², 陆丽华²^,³, 洪叶兰²^,³, 伍勇²()

¹ 中南大学湘雅医院检验科，长沙 410008
² 长沙市第一医院（中南大学湘雅医学院附属长沙医院）检验科，长沙 410005
³ 南华大学衡阳医学院长沙市第一医院研究生协作培养基地，长沙 410005

收稿日期:2025-09-26 修回日期:2026-05-04 接受日期:2026-05-06 出版日期:2026-06-25 发布日期:2026-06-27
通讯作者: 伍勇 E-mail：wuyong_xy@163.com
作者简介:作者贡献/Authors’ Contributions
李梦娜负责撰写文章，陆丽华负责收集资料，洪叶兰负责收集资料，伍勇负责提出构思及审校论文。
基金资助:
湖南省自然科学基金（青年基金）(2023JJ40066)

Research progress on antibacterial strategies against methicillin-resistant Staphylococcus aureus

LI Mengna¹^,², LU Lihua²^,³, HONG Yelan²^,³, WU Yong²()

¹ Department of Laboratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, China
² Department of Laboratory Medicine, Changsha First Hospital (Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University), Changsha 410005, China
³ Postgraduate Cooperative Training Base of Changsha First Hospital, Hengyang Medical College, University of South China, Changsha 410005, China

Received:2025-09-26 Revised:2026-05-04 Accepted:2026-05-06 Published:2026-06-25 Online:2026-06-27

摘要/Abstract

摘要：

耐甲氧西林金黄色葡萄球菌（methicillin-resistant Staphylococcus aureus，MRSA）的院内死亡率可达到20%~30%，已引起了全球关注，但目前临床上针对MRSA感染的治疗手段十分有限。MRSA的耐药机制可分为固有耐药和获得性耐药，固有耐药主要是通过分泌β-内酰胺酶和外排系统的激活实现；MRSA也可以通过基因突变或者含有耐药基因的质粒转化而获得耐药性。此外，生物膜的形成以及小菌落变异体也是其获得耐药性的重要机制。传统抗菌药物仍是目前临床治疗MRSA菌血症的主要手段。随着MRSA对传统抗菌药物的耐受性逐渐增强，对于新型治疗手段的研究也获得了巨大进展，如群体密度感应系统（quorum-sensing system，QS）抑制剂、抗菌肽、小分子化合物、抗菌光动力学疗法、噬菌体疗法以及联合用药等，都在MRSA感染治疗中有着巨大潜力，为临床提供了更高效、低毒和可持续的解决方案，也为探索不同于传统抗菌药物的作用机制的新型抗菌药物提供了新的思路。

关键词: 耐甲氧西林金黄色葡萄球菌, 耐药机制, β-内酰胺酶

Abstract:

The in-hospital mortality rate of methicillin-resistant Staphylococcus aureus (MRSA) can reach 20%-30%, which has attracted global attention. However, the clinical treatment options for MRSA infections are still very limited. The drug resistance mechanisms of MRSA can be divided into intrinsic and acquired types. Intrinsic drug resistance is mainly achieved through the secretion of β-lactamase and the activation of efflux pumps. MRSA can acquire drug resistance through gene mutations or plasmid transformation involving drug-resistant genes. Additionally, the formation of biofilms and the emergence of small colony variants are also important mechanisms for acquired drug resistance. In clinical practice, traditional antibiotics are still the main approach for treating MRSA bacteremia. As MRSA tolerance to traditional antibiotics gradually increases, research on new therapeutic methods has also made great progress. Among these, quorum-sensing system (QS) inhibitors, antimicrobial peptides, small-molecule compounds, antimicrobial photodynamic therapy, phage therapy, and combination therapy have shown great potential in the treatment of MRSA infections. These novel approaches not only provide more effective, low-toxicity, and sustainable solutions for clinical practice but also offer new ideas for the exploration of new antibiotics with mechanisms of action different from those of traditional antibiotics.

Key words: Methicillin-resistant Staphylococcus aureus, Drug resistance mechanism, β-lactamase

中图分类号:

R515

李梦娜, 陆丽华, 洪叶兰, 伍勇. 耐甲氧西林金黄色葡萄球菌抗菌策略研究进展[J]. 诊断学理论与实践, 2026, 25(03): 361-369.

LI Mengna, LU Lihua, HONG Yelan, WU Yong. Research progress on antibacterial strategies against methicillin-resistant Staphylococcus aureus[J]. Journal of Diagnostics Concepts & Practice, 2026, 25(03): 361-369.

图/表 1

参考文献 80

[1]	TONG S Y C, DAVIS J S, EICHENBERGER E, et al. Staphylococcus aureus infections: Epidemiology, pathophysiology, clinical manifestations, and management[J]. Clin Microbiol Rev, 2015, 28(3):603-661. doi: 10.1128/CMR.00134-14 URL
[2]	LÁZÁR V, SNITSER O, BARKAN D, et al. Antibiotic combinations reduce Staphylococcus aureus clearance[J]. Nature, 2022, 610(7932):540-546. doi: 10.1038/s41586-022-05260-5
[3]	World Health Organization. WHO bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance[EB/OL]. 2024[2025-10-05]. https://www.who.int/publications/i/item/9789240093461.html.
[4]	CASCIOFERRO S, CARBONE D, PARRINO B, et al. Therapeutic strategies to counteract antibiotic resistance in MRSA biofilm-associated infections[J]. ChemMedChem, 2021, 16(1):65-80. doi: 10.1002/cmdc.202000677 pmid: 33090669
[5]	陈力豪, 秦沁, 丁志广, 等. 血流感染金黄色葡萄球菌检出率及炎性因子的应用价值研究[J]. 黑龙江医药科学, 2026, 49(4):105-107.
	CHEN L H, QIN Q, DING Z G, et al. Detection rate of Staphylococcus aureus in bloodstream infection and application value of inflammatory factors[J]. Hei Long Jiang Med Pharm, 2026, 49(4):105-107.
[6]	孟鑫, 康梦娜, 李长有, 等. 金黄色葡萄球菌耐药机制及其治疗策略的进展[J]. 中国抗生素杂志, 2025, 50(12):1413-1428.
	MENG X, KANG M N, LI C Y, et al. Advances in drug resistance mechanisms and treatment strategies of Staphylococcus aureus[J]. Chin J Antibiot, 2025, 50(12):1413-1428.
[7]	LEE Y D, PARK J H. Phage conversion for β-lactam antibiotic resistance of Staphylococcus aureus from foods[J]. J Microbiol Biotechnol, 2016, 26(2):263-269. doi: 10.4014/jmb.1508.08042 URL
[8]	GUO Y, SONG G, SUN M, et al. Prevalence and therapies of antibiotic-resistance in Staphylococcus aureus[J]. Front Cell Infect Microbiol, 2020,10:107.
[9]	NAKAMINAMI H, TAKADAMA S, OKITA M, et al. Fast-acting bactericidal activity of olanexidine gluconate against qacA/B-positive methicillin-resistant Staphylococcus aureus[J]. J Med Microbiol, 2019, 68(6):957-960. doi: 10.1099/jmm.0.000979 URL
[10]	JANG S. Multidrug efflux pumps in Staphylococcus aureus and their clinical implications[J]. J Microbiol, 2016, 54(1):1-8. doi: 10.1007/s12275-016-5159-z URL
[11]	SANTOS COSTA S, SOBKOWIAK B, PARREIRA R, et al. Genetic diversity of norA, coding for a main efflux pump of Staphylococcus aureus[J]. Front Genet, 2019,9:710.
[12]	MATANO L M, MORRIS H G, HESSER A R, et al. Antibiotic that inhibits the ATPase activity of an ATP-binding cassette transporter by binding to a remote extracellular site[J]. J Am Chem Soc, 2017, 139(31):10597-10600. doi: 10.1021/jacs.7b04726 pmid: 28727445
[13]	RASHEED H, IJAZ M, AHMED A, et al. Discrepancies between phenotypic and genotypic identification methods of antibiotic resistant genes harboring Staphylococcus aureus[J]. Microb Pathog, 2023,184:106342.
[14]	MLYNARCZYK-BONIKOWSKA B, KOWALEWSKI C, KROLAK-ULINSKA A, et al. Molecular mechanisms of drug resistance in Staphylococcus aureus[J]. Int J Mol Sci, 2022, 23(15):8088. doi: 10.3390/ijms23158088 URL
[15]	KIM C, MILHEIRIÇO C, GARDETE S, et al. Properties of a novel PBP2A protein homolog from Staphylococcus aureus strain LGA251 and its contribution to the β-lactam-resistant phenotype[J]. J Biol Chem, 2012, 287(44):36854-36863. doi: 10.1074/jbc.M112.395962 URL
[16]	WANG L C, WEI Y P, CHEN J S, et al. A “signal-on” photoelectrochemical biosensor utilizing in-situ synthesis of SnS2/MgIn2S4 heterostructures and enzyme-assisted target cycling amplification for the sensitive detection of the MecA gene[J]. Talanta, 2025,293:128053.
[17]	KAUR D, CHATE S. Study of antibiotic resistance pattern in methicillin resistant Staphylococcus aureus with special reference to newer antibiotic[J]. J Global Infect Dis, 2015, 7(2):78. doi: 10.4103/0974-777X.157245 URL
[18]	TOMASZ A, DRUGEON H B, DE LENCASTRE H M, et al. New mechanism for methicillin resistance in Staphylococcus aureus: Clinical isolates that lack the PBP 2a gene and contain normal penicillin-binding proteins with modified penicillin-binding capacity[J]. Antimicrob Agents Chemother, 1989, 33(11):1869-1874. doi: 10.1128/AAC.33.11.1869 URL
[19]	ARGUDÍN M A, ROISIN S, NIENHAUS L, et al. Genetic diversity among Staphylococcus aureus isolates showing oxacillin and/or cefoxitin resistance not linked to the pre-sence of mec genes[J]. Antimicrob Agents Chemother, 2018, 62(7):e00091-e00018.
[20]	SOMMER A, FUCHS S, LAYER F, et al. Mutations in the gdpP gene are a clinically relevant mechanism for β-lactam resistance in meticillin-resistant Staphylococcus aureus lacking mec determinants[J]. Microb Genom, 2021, 7(9):000623.
[21]	DOUGLAS E J A, LAABEI M. Staph wars: the antibiotic pipeline strikes back[J]. Microbiology (Reading), 2023, 169(9):1387.
[22]	HAABER J, PENADÉS J R, INGMER H. Transfer of antibiotic resistance in Staphylococcus aureus[J]. Trends Microbiol, 2017, 25(11):893-905. doi: 10.1016/j.tim.2017.05.011 URL
[23]	VESTERGAARD M, FREES D, INGMER H. Antibiotic resistance and the MRSA problem[J]. Microbiol Spectr, 2019, 7(2):7.2.18.
[24]	LI S, HUANG W, LYU H, et al. Genomic driver underlies clonal shift of methicillin-resistant Staphylococcus aureusin the healthcare setting[J]. Emerg Microbes Infect, 2025,14:2576582.
[25]	LEE A S, DE LENCASTRE H, GARAU J, et al. Methicillin-resistant Staphylococcus aureus[J]. Nat Rev Dis Primers, 2018,4:18033.
[26]	SEAMAN P F, OCHS D, DAY M J. Small-colony variants: A novel mechanism for triclosan resistance in methicillin-resistant Staphylococcus aureus[J]. J Antimicrob Chemother, 2006, 59(1):43-50. doi: 10.1093/jac/dkl450 URL
[27]	MCNAMARA P J, PROCTOR R A. Staphylococcus aureus small colony variants, electron transport and persistent infections[J]. Int J Antimicrob Agents, 2000, 14(2):117-122. doi: 10.1016/S0924-8579(99)00170-3 URL
[28]	SEGGEWIß J, BECKER K, KOTTE O, et al. Reporter metabolite analysis of transcriptional profiles of a Staphylococcus aureus Strain with normal phenotype and its IsogenichemBMutant displaying the small-colony-variant phenotype[J]. J Bacteriol, 2006, 188(22):7765-7777. doi: 10.1128/JB.00774-06 URL
[29]	CHEN T, YE Z, HUANG W, et al. Fe-S cluster deficiency drives small colony variant formation in persistent infections[J]. J Adv Res, 2026,80:791-806.
[30]	IDREES M, SAWANT S, KARODIA N, et al. Staphylococcus aureus biofilm: Morphology, genetics, pathogenesis and treatment strategies[J]. Int J Environ Res Public Health, 2021, 18(14):7602. doi: 10.3390/ijerph18147602 URL
[31]	KAUSHIK A, KEST H, SOOD M, et al. Biofilm producing methicillin-resistant Staphylococcus aureus (MRSA) infections in humans: Clinical implications and management[J]. Pathogens, 2024, 13(1):76. doi: 10.3390/pathogens13010076 URL
[32]	WANG Q, NURXAT N, ZHANG L, et al. Diabetes mellitus promotes the nasal colonization of high virulentStaphylococcus aureus through the regulation of SaeRS two-component system[J]. Emerg Microbes Infect, 2023, 12(2):2276335. doi: 10.1080/22221751.2023.2276335 URL
[33]	HE L, ZHANG F, JIAN Y, et al. Key role of quorum-sensing mutations in the development of Staphylococcus aureus clinical device-associated infection[J]. Clin Transl Med, 2022, 12(4):e801. doi: 10.1002/ctm2.v12.4 URL
[34]	FISHER R A, GOLLAN B, HELAINE S. Persistent bacterial infections and persister cells[J]. Nat Rev Microbiol, 2017, 15(8):453-464. doi: 10.1038/nrmicro.2017.42 pmid: 28529326
[35]	LIU C, BAYER A, COSGROVE S E, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children[J]. Clin Infect Dis, 2011, 52(3):e18-e55. doi: 10.1093/cid/ciq146 URL
[36]	STEVENS D L, DOTTER B, MADARAS-KELLY K. A review of linezolid: The first oxazolidinone antibiotic[J]. Expert Rev Anti Infect Ther, 2004, 2(1):51-59. doi: 10.1586/14787210.2.1.51 URL
[37]	BRUNIERA F R, FERREIRA F M, SAVIOLLI L R M, et al. The use of vancomycin with its therapeutic and adverse effects: a review[J]. Eur Rev Med Pharmacol Sci, 2015, 19(4):694-700.
[38]	MICEK S T. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections[J]. Clin Infect Dis, 2007, 45(Supplement_3):S184-S190. doi: 10.1086/519471 URL
[39]	HASEEB A, AJIT SINGH V, TEH C S J, et al. Addition of ceftaroline fosamil or vancomycin to PMMA: An in vitro comparison of biomechanical properties and anti-MRSA efficacy[J]. J Orthop Surg (Hong Kong), 2019, 27(2):2309499019850324. doi: 10.1177/2309499019850324 URL
[40]	GAUDARD P, SAOUR M, MORQUIN D, et al. Acute kidney injury during daptomycin versus vancomycin treatment in cardiovascular critically ill patients: A propensity score matched analysis[J]. BMC Infect Dis, 2019, 19(1):438. doi: 10.1186/s12879-019-4077-1 pmid: 31109283
[41]	HEIDARY M, KHOSRAVI A D, KHOSHNOOD S, et al. Daptomycin[J]. J Antimicrob Chemother, 2018, 73(1):1-11. doi: 10.1093/jac/dkx349 pmid: 29059358
[42]	TONG S Y C, NELSON J, PATERSON D L, et al. CAMERA2-combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: Study protocol for a randomised controlled trial[J]. Trials, 2016, 17(1):170. doi: 10.1186/s13063-016-1295-3 URL
[43]	BIRMINGHAM M C, RAYNER C R, MEAGHER A K, et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: Experience from a compassionate-use program[J]. Clin Infect Dis, 2003, 36(2):159-168. doi: 10.1086/345744 pmid: 12522747
[44]	AMENT P W, JAMSHED N, HORNE J P. Linezolid: its role in the treatment of gram-positive, drug-resistant bacterial infections[J]. Am Fam Physician, 2002, 65(4):663-670. pmid: 11871684
[45]	HASHEMIAN S M, FARHADI T, GANJPARVAR M. Linezolid: A review of its properties, function, and use in critical care[J]. Drug Des Dev Ther, 2018,12:1759-1767.
[46]	DRAGHI D C, BENTON B M, KRAUSE K M, et al. Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States[J]. Antimicrob Agents Chemother, 2008, 52(7):2383-2388. doi: 10.1128/AAC.01641-07 pmid: 18443115
[47]	DAS B, SARKAR C, DAS D, et al. Telavancin: A novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens[J]. Therapeutic Advances Infection, 2017, 4(2):49-73. doi: 10.1177/2049936117690501 URL
[48]	JAME W, BASGUT B, ABDI A. Efficacy and safety of novel glycopeptides versus vancomycin for the treatment of gram-positive bacterial infections including methicillin resistant Staphylococcus aureus: A systematic review and meta-analysis[J]. PLoS One, 2021, 16(11):e0260539. doi: 10.1371/journal.pone.0260539 URL
[49]	BIEDENBACH D J, BOUCHILLON S K, JOHNSON B, et al. In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China[J]. Eur J Clin Microbiol Infect Dis,2016, 35(12):1933-1939. doi: 10.1007/s10096-016-2744-3 URL
[50]	LOCKE J B, FINN J, HILGERS M, et al. Structure-activity relationships of diverse oxazolidinones for linezolid-Resistant Staphylococcus aureus Strains possessing the cfr Methyltransferase gene or ribosomal mutations[J]. Antimicrob Agents Chemother, 2010, 54(12):5337-5343. doi: 10.1128/AAC.00663-10 URL
[51]	GRAU S, FERRÁNDEZ O, URBINA O, et al. Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections[J]. Drug Des Dev Ther,2013:243.
[52]	HASANNEJAD-BIBALAN M, MOJTAHEDI A, BIGLARI H, et al. Antibacterial activity of tedizolid, a novel oxazolidinone against methicillin-Resistant Staphylococcus aureus: A systematic review and meta-analysis[J]. Microb Drug Resist, 2019, 25(9):1330-1337. doi: 10.1089/mdr.2018.0457 URL
[53]	HASSOUN A, LINDEN P K, FRIEDMAN B. Incidence, prevalence, and management of MRSA bacteremia across patient populations: A review of recent developments in MRSA management and treatment[J]. Crit Care, 2017, 21(1):211. doi: 10.1186/s13054-017-1801-3 URL
[54]	LI J, LIU D, TIAN X, et al. Novel antibacterial modalities against methicillin resistant Staphylococcus aureus derived from plants[J]. Crit Rev Food Sci Nutr, 2019, 59(sup1):S153-S161. doi: 10.1080/10408398.2018.1541865 URL
[55]	ANTUNES L C M, FERREIRA R B R, BUCKNER M M C, et al. Quorum sensing in bacterial virulence[J]. Microbiology, 2010, 156(8):2271-2282. doi: 10.1099/mic.0.038794-0 URL
[56]	KAUR B, GUPTA J, SHARMA S, et al. Focused review on dual inhibition of quorum sensing and efflux pumps: A potential way to combat multi drug resistant Staphylococcus aureus infections[J]. Int J Biol Macromol, 2021,190:33-43.
[57]	PARLET C P, KAVANAUGH J S, CROSBY H A, et al. Apicidin attenuates MRSA virulence through quorum-sensing inhibition and enhanced host defense[J]. Cell Rep, 2019, 27(1):187-198,e6. doi: S2211-1247(19)30325-0 pmid: 30943400
[58]	LU X, WANG G, XIE Y, et al. Efflux pump inhibitor combined with ofloxacin decreases MRSA biofilm formation by regulating the gene expression of NorA and quorum sensing[J]. RSC Adv, 2023, 13(4):2707-2717. doi: 10.1039/d2ra06696c pmid: 36741169
[59]	KHAN S A, DOUGHERTY T J, MANG T S. An evaluation of photodynamic therapy in the management of cutaneous metastases of breast cancer[J]. Eur J Cancer, 1993, 29(12):1686-1690. doi: 10.1016/0959-8049(93)90105-O URL
[60]	DHARMARATNE P, SAPUGAHAWATTE D N, WANG B, et al. Contemporary approaches and future perspectives of antibacterial photodynamic therapy (aPDT) against methicillin-resistant Staphylococcus aureus (MRSA): A systematic review[J]. Eur J Med Chem, 2020,200:112341.
[61]	USACHEVA M N, TEICHERT M C, BIEL M A. Comparison of the methylene blue and toluidine blue photobactericidal efficacy against gram-positive and gram-negative microorganisms[J]. Lasers Surg Med, 2001, 29(2):165-173. doi: 10.1002/lsm.v29:2 URL
[62]	ZHANG A, WU H, CHEN X, et al. Targeting and arginine-driven synergizing photodynamic therapy with nutritional immunotherapy nanosystems for combating MRSA biofilms[J]. Sci Adv, 2023, 9(28):eadg9116.
[63]	ÑOPO L, WOFFENDEN B J, REED D G, et al. Super-promoter: TEV a powerful gene expression system for tobacco hairy roots[M]// Recombinant Gene Expression. Totowa,NJ: Humana Press,2011:501-526.
[64]	GANESAN N, MISHRA B, FELIX L, et al. Antimicrobial peptides and small molecules targeting the cell membrane of Staphylococcus aureus[J]. Microbiol Mol Biol Rev, 2023, 87(2):e00037-e00022.
[65]	SHE P, LIU Y, XU L, et al. L007-0069 kills Staphylococcus aureus in high resistant phenotypes[J]. Cell Mol Life Sci, 2022, 79(11):552. doi: 10.1007/s00018-022-04588-5
[66]	DE BREIJ A, RIOOL M, CORDFUNKE R A, et al. The antimicrobial peptide SAAP-148 combats drug-resistant bacteria and biofilms[J]. Sci Transl Med, 2018, 10(423):eaan4044. doi: 10.1126/scitranslmed.aan4044 URL
[67]	ZHOU J, WANG Z, YANG C, et al. A carrier-free, dual-functional hydrogel constructed of antimicrobial peptide Jelleine-1 and 8Br-cAMP for MRSA infected diabetic wound healing[J]. Acta Biomater, 2022,151:223-234.
[68]	MISHRA B, BASU A, SHEHADEH F, et al. Antimicrobial peptide developed with machine learning sequence optimization targets drug resistant Staphylococcus aureus in mice[J]. J Clin Investig, 2025, 135(12):e185430. doi: 10.1172/JCI185430 URL
[69]	LI L, ZHONG Q, ZHAO Y, et al. First-in-human application of double-stranded RNA bacteriophage in the treatment of pulmonary Pseudomonas aeruginosa infection[J]. Microb Biotechnol, 2023, 16(4):862-867. doi: 10.1111/mbt2.v16.4 URL
[70]	CHANISHVILI N. Phage therapy: History from twort and d’Herelle through soviet experience to current approaches[M]// Bacteriophages, Part B. Amsterdam: Elsevier,2012:3-40.
[71]	GÓRSKI A, BORYSOWSKI J, MIĘDZYBRODZKI R. Phage therapy: Towards a successful clinical trial[J]. Antibiotics, 2020, 9(11):827. doi: 10.3390/antibiotics9110827 URL
[72]	GORDILLO ALTAMIRANO F L, BARR J J. Phage therapy in the postantibiotic era[J]. Clin Microbiol Rev, 2019, 32(2):e00066-e00018.
[73]	LIU S, HON K, BOURAS G S, et al. APTC-C-SA01: A novel bacteriophage cocktail targeting Staphylococcus aureus and MRSA biofilms[J]. Int J Mol Sci, 2022, 23(11):6116. doi: 10.3390/ijms23116116 URL
[74]	DOUB J B, NG V Y, LEE M, et al. Salphage: Salvage bacteriophage therapy for recalcitrant MRSA prosthetic joint infection[J]. Antibiotics, 2022, 11(5):616. doi: 10.3390/antibiotics11050616 URL
[75]	LEITNER L, UJMAJURIDZE A, CHANISHVILI N, et al. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: A randomised, placebo-controlled, double-blind clinical trial[J]. Lancet Infect Dis, 2021, 21(3):427-436. doi: 10.1016/S1473-3099(20)30330-3 pmid: 32949500
[76]	DE WIT J, TOTTÉ J E E, VAN MIERLO M M F, et al. Endolysin treatment against Staphylococcus aureus in adults with atopic dermatitis: A randomized controlled trial[J]. J Allergy Clin Immunol, 2019, 144(3):860-863. doi: 10.1016/j.jaci.2019.05.020 URL
[77]	FORTALEZA J A G, ONG C J N, DE JESUS R. Efficacy and clinical potential of phage therapy in treating methicillin-resistant Staphylococcus aureus (MRSA) infections: A review[J]. EuJMI, 2024, 14(1):13-25. doi: 10.1556/1886.2023.00064 URL
[78]	BECKER S C, FOSTER-FREY J, DONOVAN D M. The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA[J]. FEMS Microbiol Lett, 2008, 287(2):185-191. doi: 10.1111/j.1574-6968.2008.01308.x pmid: 18721148
[79]	ROSE W, FANTL M, GERIAK M, et al. Current paradigms of combination therapy in methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: Does it work, which combination, and for which patients?[J]. Clin Infect Dis, 2021, 73(12):2353-2360. doi: 10.1093/cid/ciab452 URL
[80]	ABDELAZIZ A A, EL-BARRAWY M A, EL-NAGAR R A M. Potent synergistic combination of rosuvastatin and levofloxacin against Staphylococcus aureus: in vitro and in vivo study[J]. J Appl Microbiol, 2021, 131(1):182-196. doi: 10.1111/jam.v131.1 URL

耐甲氧西林金黄色葡萄球菌抗菌策略研究进展

Research progress on antibacterial strategies against methicillin-resistant Staphylococcus aureus

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 80

相关文章 7

编辑推荐

Metrics

本文评价

[1]	沈平华, 陈慧芬. B组链球菌对大环内酯和林可酰胺类抗生素耐药机制的研究进展[J]. 诊断学理论与实践, 2025, 24(06): 654-659.
[2]	沈平华, 陈慧芬. 新型四环素灭活酶tet(X)致替加环素耐药的机制研究进展[J]. 诊断学理论与实践, 2023, 22(01): 75-79.
[3]	王院霞, 姚锂凤, 郑巧平, 陈旭. 9株分离自住院患者的CA-MRSA基因型菌株的分子特征及耐药性研究[J]. 诊断学理论与实践, 2021, 20(01): 66-70.
[4]	邓正泊,. 阴沟肠杆菌临床分布特征及耐药性变迁[J]. 诊断学理论与实践, 2013, 12(04): 448-451.
[5]	史册, 刘锦燕, 魏冰, 项明洁,. 白假丝酵母对氟康唑耐药机制的研究进展[J]. 诊断学理论与实践, 2013, 12(03): 372-375.
[6]	李耀华, 费春荣, 叶爱青,. 实时荧光PCR快速检测耐甲氧西林金黄色葡萄球菌的临床评估[J]. 诊断学理论与实践, 2011, 10(05): 449-453.
[7]	刘瑛,张蓓,沈立松. 4种检测耐甲氧西林金黄色葡萄球菌方法的评估[J]. 诊断学理论与实践, 2005, 4(03): 225-227.